The cancer drug Sutent, one of at least three Glivec-like "smart" drugs in various stages of development, has become available in the U.K. Regulators cleared Sutent for use in treating kidney cancer and gatrointestinal stromal tumors, and the drug is being tested for use against breast, lung and pancreatic cancers.

Related Summaries